Abeona Therapeutics Inc (ABEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs include ABO-101 and ABO-102 adeno-associated virus. Abeona is also develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 for rare blood diseases. The company has partnership with for the commercialization of its products in the US, European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia, New Zealand, China and South Korea. Abeona is headquartered in Dallas, Texas, the US.

Abeona Therapeutics Inc (ABEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 6
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15
Abeona Therapeutics Raises US$0.75 Million In Seed Financing 16
Partnerships 17
Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17
Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18
Licensing Agreements 19
Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19
Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22
PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23
PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24
Access Pharma Enters into Licensing Agreement with Plasma Technologies 25
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29
Equity Offering 30
Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30
Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31
Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33
Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37
Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38
PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39
PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40
PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41
Access Pharma Completes Private Placement Of Units For US$4.7 Million 43
Access Pharma Files Registration Statement For Public Offering Of Units 44
Acquisition 45
PlasmaTech Biopharma Acquires Abeona Therapeutics 45
Abeona Therapeutics Inc - Key Competitors 46
Abeona Therapeutics Inc - Key Employees 47
Abeona Therapeutics Inc - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 49
Strategy And Business Planning 49
Oct 04, 2017: Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio 49
Financial Announcements 50
Aug 09, 2018: Abeona Therapeutics reports second quarter 2018 financial results and business highlights 50
May 11, 2018: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights 52
Mar 16, 2018: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights 54
Nov 15, 2017: Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights 55
Aug 15, 2017: Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 56
May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 58
Mar 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights 60
Corporate Communications 62
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 62
May 14, 2018: Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors 63
Apr 02, 2018: Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer 64
Jul 25, 2017: Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer 65
Legal and Regulatory 66
Feb 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit 66
Government and Public Interest 67
Oct 16, 2017: Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies 67
Product News 68
12/20/2017: Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB 68
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 69
05/17/2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting 70
05/12/2017: Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT 71
05/09/2017: Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA 72
05/08/2017: Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting 73
05/02/2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference 74
04/25/2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting 76
02/17/2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium 2017 78
02/07/2018: Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial 80
02/07/2017: Abeona Therapeutics Presents Data on ABO-102 at the 13th Annual WORLDSymposium 2017 82
02/07/2017: Abeona Therapeutics Presents Data on ABO-201 at the 13th Annual WORLDSymposium 2017 83
02/01/2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A 84
Product Approvals 85
May 30, 2017: Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 85
May 25, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 87
Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa 88
Jan 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B 89
Jan 03, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease 90
Clinical Trials 91
Jan 29, 2018: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa 91
Aug 29, 2017: Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa 92
Aug 17, 2017: Abeona Therapeutics Provides Update on EB-101 at R&D Day on October 11, 2017 93
Aug 16, 2017: Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A 94
Jul 18, 2017: Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa 95
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96

List Of Tables


Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15
Abeona Therapeutics Raises US$0.75 Million In Seed Financing 16
Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17
Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18
Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19
Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22
PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23
PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24
Access Pharma Enters into Licensing Agreement with Plasma Technologies 25
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29
Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30
Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31
Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33
Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37
Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38
PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39
PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40
PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41
Access Pharma Completes Private Placement Of Units For US$4.7 Million 43
Access Pharma Files Registration Statement For Public Offering Of Units 44
PlasmaTech Biopharma Acquires Abeona Therapeutics 45
Abeona Therapeutics Inc, Key Competitors 46
Abeona Therapeutics Inc, Key Employees 47
Abeona Therapeutics Inc, Subsidiaries 48

List Of Figures


Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Abeona Therapeutics Inc (ABEO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead

USD 250 View Report

Abeona Therapeutics Inc (ABEO) - Financial and Strategic SWOT Analysis Review

Abeona Therapeutics Inc (ABEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125 View Report

Anika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2019 Update

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products

USD 750 View Report

Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD)

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available